A citation-based method for searching scientific literature

Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.
Nils Ekström, Linus Schiöler, Ann-Marie Svensson, Katarina Eeg-Olofsson, Junmei Miao Jonasson, Björn Zethelius, Jan Cederholm, Björn Eliasson, Soffia Gudbjörnsdottir. BMJ Open 2012
151
50


Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Serge A Jabbour, Juan P Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C David Sjöström, Cristian Guja. Diabetes Care 2020
5
50

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass,[...]. Circulation 2021
43
50

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
50

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
486
50

ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Yaru Zhang, Dandan He, Wei Zhang, Yue Xing, Yipeng Guo, Fuzhen Wang, Junya Jia, Tiekun Yan, Youxia Liu, Shan Lin. Drugs 2020
13
50

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
188
50

Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death.
Abeba M Berhane, E Jennifer Weil, William C Knowler, Robert G Nelson, Robert L Hanson. Clin J Am Soc Nephrol 2011
90
50

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
Gemma Currie, Alison H M Taylor, Toshiro Fujita, Hiroshi Ohtsu, Morten Lindhardt, Peter Rossing, Lene Boesby, Nicola C Edwards, Charles J Ferro, Jonathan N Townend,[...]. BMC Nephrol 2016
66
50

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
263
50

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
50

Effects of dietary interventions on incidence and progression of CKD.
Nishank Jain, Robert F Reilly. Nat Rev Nephrol 2014
31
50

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
271
50

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
Benjamin Lazarus, Aozhou Wu, Jung-Im Shin, Yingying Sang, G Caleb Alexander, Alex Secora, Lesley A Inker, Josef Coresh, Alex R Chang, Morgan E Grams. JAMA Intern Med 2018
62
50

Changes in diabetes-related complications in the United States, 1990-2010.
Edward W Gregg, Yanfeng Li, Jing Wang, Nilka Rios Burrows, Mohammed K Ali, Deborah Rolka, Desmond E Williams, Linda Geiss. N Engl J Med 2014
925
50

Global estimates of the prevalence of diabetes for 2010 and 2030.
J E Shaw, R A Sicree, P Z Zimmet. Diabetes Res Clin Pract 2010
50

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N Engl J Med 2017
146
50


Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications.
Eleftheria Papachristoforou, Vaia Lambadiari, Eirini Maratou, Konstantinos Makrilakis. J Diabetes Res 2020
21
50

Temporal trends in the prevalence of diabetic kidney disease in the United States.
Ian H de Boer, Tessa C Rue, Yoshio N Hall, Patrick J Heagerty, Noel S Weiss, Jonathan Himmelfarb. JAMA 2011
587
50

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Sergei Petrykiv, C David Sjöström, Peter J Greasley, John Xu, Frederik Persson, Hiddo J L Heerspink. Clin J Am Soc Nephrol 2017
82
50

Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.
Esteban Porrini, Piero Ruggenenti, Carl Erik Mogensen, Drazenka Pongrac Barlovic, Manuel Praga, Josep M Cruzado, Radovan Hojs, Manuela Abbate, Aiko P J de Vries. Lancet Diabetes Endocrinol 2015
103
50


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
50


Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies.
Marco Fiorentino, Davide Bolignano, Vladimir Tesar, Anna Pisano, Wim Van Biesen, Giovanni Tripepi, Graziella D'Arrigo, Loreto Gesualdo. Nephrol Dial Transplant 2017
55
50

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
Toshiharu Ninomiya, Vlado Perkovic, Bastiaan E de Galan, Sophia Zoungas, Avinesh Pillai, Meg Jardine, Anushka Patel, Alan Cass, Bruce Neal, Neil Poulter,[...]. J Am Soc Nephrol 2009
595
50

The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
Soie Kwon, Yong Chul Kim, Jae Yoon Park, Jeonghwan Lee, Jung Nam An, Clara Tammy Kim, Sohee Oh, Seokwoo Park, Dong Ki Kim, Yun Kyu Oh,[...]. Diabetes Care 2020
29
50

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Patricia Y Chu, Amber J Hackstadt, Jonathan Chipman, Marie R Griffin, Adriana M Hung, Robert A Greevy, Carlos G Grijalva, Tom Elasy, Christianne L Roumie. Diabetes Care 2020
7
50

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Susan J Bersoff-Matcha, Christine Chamberlain, Christian Cao, Cindy Kortepeter, William H Chong. Ann Intern Med 2019
87
50

The potential for renoprotection with incretin-based drugs.
Tetsuhiro Tanaka, Yoshiki Higashijima, Takehiko Wada, Masaomi Nangaku. Kidney Int 2014
72
50

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Jens Oellgaard, Peter Gæde, Peter Rossing, Frederik Persson, Hans-Henrik Parving, Oluf Pedersen. Kidney Int 2017
49
50

Translating the A1C assay into estimated average glucose values.
David M Nathan, Judith Kuenen, Rikke Borg, Hui Zheng, David Schoenfeld, Robert J Heine. Diabetes Care 2008
911
50

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun. Sci Rep 2017
86
50

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
50

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
291
50

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Tim Heise, Jens Jordan, Christoph Wanner, Martina Heer, Sreeraj Macha, Michaela Mattheus, Søren S Lund, Hans J Woerle, Uli C Broedl. Clin Ther 2016
50
50

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Muh Geot Wong, Vlado Perkovic, John Chalmers, Mark Woodward, Qiang Li, Mark E Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon,[...]. Diabetes Care 2016
104
50

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
150
50

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske. Diabetes Obes Metab 2020
5
50

Metformin use and mortality among patients with diabetes and atherothrombosis.
Ronan Roussel, Florence Travert, Blandine Pasquet, Peter W F Wilson, Sidney C Smith, Shinya Goto, Philippe Ravaud, Michel Marre, Avi Porath, Deepak L Bhatt,[...]. Arch Intern Med 2010
244
50

Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.
Leila R Zelnick, Zona O Batacchi, Iram Ahmad, Ashveena Dighe, Randie R Little, Dace L Trence, Irl B Hirsch, Ian H de Boer. Diabetes Care 2020
6
50



Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
50

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
434
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.